Semaglutide extends lifespan in old female mice, with no human longevity result yet

What happened

Semaglutide extended median lifespan and improved several measures of late-life function in old female mice, according to a study published September 2 in *Nature*. The result suggests that activating the GLP-1 receptor may influence aging biology beyond the consequences of eating less, but it remains a finding from one sex and one inbred mouse strain.

Researchers began treating healthy, 20-month-old female C57BL/6 mice, an advanced age for the animals. In the survival experiment, 40 mice received daily semaglutide injections and 39 received saline for the remainder of their lives. Median lifespan increased from 742 days in the control group to 834 days with semaglutide—a 92-day, or 12.4%, difference.

That is a lifespan result in mice, not evidence that semaglutide extends human life. The study did not enroll people, establish a longevity indication or determine the balance of benefits and harms if the drug were given to otherwise healthy older adults.

Separating drug effects from reduced food intake

Semaglutide activates the GLP-1 receptor and commonly reduces appetite. Because calorie restriction can extend lifespan and preserve function in laboratory animals, reduced food intake is an important alternative explanation for the findings.

The treated mice ate approximately 24% less food. To investigate that issue, the researchers ran a separate five-month experiment involving 10 mice per group: semaglutide, saline control or calorie restriction matched to the average reduction in food intake produced by the drug. This comparison assessed functional and biological trajectories; it was not a calorie-restriction lifespan experiment.

Many outcomes remained stable in both the semaglutide and calorie-restricted groups as untreated mice declined. Semaglutide-treated animals performed better than the calorie-restricted group on exploratory behavior, spatial memory and glucose control. Their metabolic rate also remained largely unchanged, whereas it declined with calorie restriction. Those differences support the possibility of drug effects beyond lower calorie consumption, although they do not identify a single causal pathway.

Multiple aging-related endpoints moved

Separate cohorts treated for three months underwent physiological, molecular and cellular testing. Semaglutide improved measures related to muscle performance, exercise endurance, cognition and glucose regulation. Analyses of the liver, skeletal muscle, brain and blood-forming system also found changes in inflammation, stress responses, nutrient sensing and regenerative capacity.

Gene-expression patterns shifted in directions broadly opposed to several age-associated changes. Genes that normally increased with age and were suppressed by treatment were enriched for inflammation and lipid metabolism, while some genes induced by semaglutide were associated with adaptive immunity, DNA repair and glucose or insulin responses.

These measurements strengthen the case that the survival finding was accompanied by broader physiological changes. They do not prove that any particular molecular change caused the animals to live longer. Testing many correlated endpoints also makes it difficult to determine which effects are central and which accompany weight loss or improved metabolic health.

Why translation remains uncertain

The most immediate limitation is biological scope. Only female C57BL/6 mice were tested; the investigators selected females partly to avoid injuries associated with aggression among group-housed males. Results could differ in males, other mouse strains, animals with different diets or genetically diverse populations.

The regimen also involved daily injections under controlled laboratory conditions. Human semaglutide use occurs in clinically selected populations, with dosing schedules, comorbidities and adverse-effect risks that cannot be inferred from this experiment. No treatment-attributable adverse effects were observed among the endpoints monitored in the mice, but the study was not designed to establish long-term safety in healthy people. Loss of lean or muscle mass remains a particular translational concern for older adults.

The practical conclusion is therefore narrow: late-life GLP-1 receptor activation extended median survival in this mouse model, and food-matched comparisons suggest that some functional effects may not be explained solely by reduced calorie intake. Determining whether semaglutide alters human aging trajectories would require long-duration clinical studies with prespecified functional, safety and mortality endpoints. Until such evidence exists, the mouse result should not be treated as support for using semaglutide as a human longevity therapy.